Revatis S.A. • Production and supply of human stem cells

Revatis focuses on R&D projects, preclinical studies, non-therapeutic applications and tissue engineering.

Research & Development

Production of muscle derived mesenchymal stem cells

By using its innovative, minimally invasive and patented technology for obtaining multipotent stem cells, Revatis is able to provide its partners with an affordable and reliable supply of stem cells for their R&D and preclinical applications.

Perspectives in personalized medicine

Less invasive sampling facilitates autologous use and personalized medicine applications, both diagnostic and tissue engineering such as 3D bioprinting.

Perspectives in personalized medicine
Focus on the quality of production

Cell production in aseptic isolator, quality management system and GMP certification ensure stable and high quality supply.

Focus on the quality of production
High level scientific environment

The team is very experienced in the differentiation, culture, production and quality control of stem cells as well as in the management of research projects.

High level scientific environment
Strong intellectual property

Revatis shares patents, knowledge and know-how with its partners.

Strong intellectual property

Muscle derived mesenchymal stem cells

The stem cells developed by Revatis exhibit high multipotency, remarkable paracrine effects and immunomodulatory properties targeting not only lymphocytes, macrophages but also neutrophils.

Revatis technology provides a population of stem cells that comply with the guidelines of the International Society for Cell Therapy (ISCT).

See Biobanking

Biobanking

Revatis has an accredited biobank of stem cells for R & D from muscle biopsies performed on healthy volunteers.

See Therapeutic use

Therapeutic use

Revatis establishes agreements with human body material banks to position itself as an "intermediate structure" for the production of clinical batches for immediate or deferred use

Our team

Benjamin Damien

Business Development

Benjamin Damien

Didier Serteyn

CEO

Didier Serteyn

Justine Ceusters

CSO/COO

Justine Ceusters

Hélène Graide

Production Management

Hélène Graide

Julien Duysens

Production Assistant

Julien Duysens

Alison Fraikin

Supply Chain Associate

Alison Fraikin

Ambitions and objectives

Our ambition is to become a major player in the use of cell therapy in personalized medicine. Our objective is to use the results of clinical studies in animals as a preclinical study in humans.

Actualities

Read the articl

Participation of Revatis in the BIO congress

Read the articl

New IP publications in US

Read the articl

BIOEUROPE Spring

All the articles